- Home
- WDC vs BIIB Comparison
WDC vs BIIB Comparison
Compare WDC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDC
- BIIB
- Stock Information
- Founded
- WDC 1970
- BIIB 1978
- Country
- WDC United States
- BIIB United States
- Employees
- WDC N/A
- BIIB N/A
- Industry
- WDC Electronic Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WDC Technology
- BIIB Health Care
- Exchange
- WDC Nasdaq
- BIIB Nasdaq
- Market Cap
- WDC 24.7B
- BIIB 25.1B
- IPO Year
- WDC N/A
- BIIB 1991
- Fundamental
- Price
- WDC $73.43
- BIIB $164.23
- Analyst Decision
- WDC Buy
- BIIB Buy
- Analyst Count
- WDC 21
- BIIB 25
- Target Price
- WDC $89.42
- BIIB $258.57
- AVG Volume (30 Days)
- WDC 5.0M
- BIIB 1.7M
- Earning Date
- WDC 01-23-2025
- BIIB 10-30-2024
- Dividend Yield
- WDC N/A
- BIIB N/A
- EPS Growth
- WDC N/A
- BIIB 10.05
- EPS
- WDC 0.99
- BIIB 11.06
- Revenue
- WDC $14,348,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- WDC $31.62
- BIIB N/A
- Revenue Next Year
- WDC $10.73
- BIIB N/A
- P/E Ratio
- WDC $73.98
- BIIB $14.85
- Revenue Growth
- WDC 26.61
- BIIB N/A
- 52 Week Low
- WDC $46.47
- BIIB $153.62
- 52 Week High
- WDC $81.55
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- WDC 64.86
- BIIB 42.84
- Support Level
- WDC $62.82
- BIIB $158.44
- Resistance Level
- WDC $71.23
- BIIB $160.63
- Average True Range (ATR)
- WDC 2.13
- BIIB 4.14
- MACD
- WDC 0.96
- BIIB 0.94
- Stochastic Oscillator
- WDC 95.78
- BIIB 47.71
About WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.